InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,620.85
(
0.42%
)
US TECH 100
19,332.00
(
0.63%
)
Dow Jones
40,890.49
(
0.14%
)
Brent Oil
75.64
(
-0.07%
)
Bitcoin
60,932.54
(
3.26%
)
Post# of 252939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120317
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 89755

Tuesday, 04/20/2010 6:19:44 PM

Tuesday, April 20, 2010 6:19:44 PM

Post# of 252939
GILD HCV Update from 1Q10 CC

• GILD has three HCV drugs in phase-1 trials that they will not discuss for competitive reasons. (These are in addition to GILD’s two known HCV drug candidates: the non-nuke, GS9190, and the PI, GS9256.)

• Enrollment is “brisk” in GILD’s all-oral phase-2a trial of GS9256 + GS9190 with and without ribavirin. Preliminary data is expected in 2H10.

• GILD says they are still “assessing the data” to determine what to do with the GS91900+SoC program but, as previously noted, I don’t think this program is viable (#msg-46036072).


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up